中国卫生产业
中國衛生產業
중국위생산업
CHINA HEALTH INDUSTRY
2014年
30期
16-17
,共2页
干扰素%病毒唑%慢性慢性乙型肝炎%临床疗效
榦擾素%病毒唑%慢性慢性乙型肝炎%臨床療效
간우소%병독서%만성만성을형간염%림상료효
Interferon%Ribavirin%Chronic hepatitis B%Clinical effect
目的：观察分析干扰素联合病毒唑治疗慢性乙型肝炎的临床疗效以及安全性。方法回顾性分析我院于2012年5月-2013年6月收治的160例慢性乙型肝炎患者的病历资料，随机的分为对照组和治疗组，对照组和治疗组各80例，对照组中的80例慢性乙型肝炎患者采取单用干扰素治疗，治疗组中的80例慢性乙型肝炎患者采取干扰素联合病毒唑治疗，观察分析两组慢性乙型肝炎患者治疗前后的症状体征的改善程度、生化应答率、病毒应答率以及不良反应的发生情况。结果经治疗，对照组临床症状改善率为78%，病毒应答率为45%，生化应答率为72%。治疗组临床症状改善率为78%，病毒应答率为45%，生化应答率为72%，两组间治疗之后的临床症状改善率、病毒应答率以及生化应答率进行比较，P>0.05，无统计学意义。对照组的持续应答率为17%，治疗组持续应答率为46%，两组间的持续应答率进行比较，P<0.05，有统计学意义。结论干扰素联合病毒唑治疗慢性乙型肝炎临床疗效尤为显著，不仅仅将慢性乙型肝炎患者的抗病毒治疗疗效增强，同时又有着良好的耐受性，有着一定的可行性和安全性，值得临床推广。
目的：觀察分析榦擾素聯閤病毒唑治療慢性乙型肝炎的臨床療效以及安全性。方法迴顧性分析我院于2012年5月-2013年6月收治的160例慢性乙型肝炎患者的病歷資料，隨機的分為對照組和治療組，對照組和治療組各80例，對照組中的80例慢性乙型肝炎患者採取單用榦擾素治療，治療組中的80例慢性乙型肝炎患者採取榦擾素聯閤病毒唑治療，觀察分析兩組慢性乙型肝炎患者治療前後的癥狀體徵的改善程度、生化應答率、病毒應答率以及不良反應的髮生情況。結果經治療，對照組臨床癥狀改善率為78%，病毒應答率為45%，生化應答率為72%。治療組臨床癥狀改善率為78%，病毒應答率為45%，生化應答率為72%，兩組間治療之後的臨床癥狀改善率、病毒應答率以及生化應答率進行比較，P>0.05，無統計學意義。對照組的持續應答率為17%，治療組持續應答率為46%，兩組間的持續應答率進行比較，P<0.05，有統計學意義。結論榦擾素聯閤病毒唑治療慢性乙型肝炎臨床療效尤為顯著，不僅僅將慢性乙型肝炎患者的抗病毒治療療效增彊，同時又有著良好的耐受性，有著一定的可行性和安全性，值得臨床推廣。
목적：관찰분석간우소연합병독서치료만성을형간염적림상료효이급안전성。방법회고성분석아원우2012년5월-2013년6월수치적160례만성을형간염환자적병력자료，수궤적분위대조조화치료조，대조조화치료조각80례，대조조중적80례만성을형간염환자채취단용간우소치료，치료조중적80례만성을형간염환자채취간우소연합병독서치료，관찰분석량조만성을형간염환자치료전후적증상체정적개선정도、생화응답솔、병독응답솔이급불량반응적발생정황。결과경치료，대조조림상증상개선솔위78%，병독응답솔위45%，생화응답솔위72%。치료조림상증상개선솔위78%，병독응답솔위45%，생화응답솔위72%，량조간치료지후적림상증상개선솔、병독응답솔이급생화응답솔진행비교，P>0.05，무통계학의의。대조조적지속응답솔위17%，치료조지속응답솔위46%，량조간적지속응답솔진행비교，P<0.05，유통계학의의。결론간우소연합병독서치료만성을형간염림상료효우위현저，불부부장만성을형간염환자적항병독치료료효증강，동시우유착량호적내수성，유착일정적가행성화안전성，치득림상추엄。
Objective To observe and analyze the interferon combined with ribavirin in the treatment of chronic hepatitis B clini-cal efficacy and safety. Methods A retrospective analysis of our hospital in 2012 May ~2013 year in June 160 cases of chronic hepatitis B patients medical records, randomly divided into control group and treatment group, control group and treatment group with 80 cases in each group, 80 cases of chronic hepatitis B patients in the control group treated only with interferon in treatment group, 80 patients with chronic hepatitis B to interferon and ribavirin, observing the improvement degree of occurrence, clinical symptoms and signs of the two groups before and after treatment in patients with chronic hepatitis B virus biochemical response rate, response rate and adverse reaction of. Results After treatment, the control group in improving clinical symptoms was 78%, vi-ral response rate was 45%, biochemical response rate 72%. The clinical symptom improvement rate was 78%, viral response rate was 45%, biochemical response rate was 72%, between the two groups after treatment, clinical symptom improvement rate, viral re-sponse rate and compared, biochemical response rate of P>0.05, no statistical significance. The sustained response rate was 17%in control group, the treatment group the sustained response rate was 46%, the rate of sustained response between the two groups were compared, P<0.05, there was statistical significance. Conclusion Interferon combined with ribavirin for the treatment of chronic hepatitis B is very significant, not only will enhance the efficacy of antiviral therapy in patients with chronic hepatitis B, and has a good tolerance, the feasibility and safety of certain, is worth the clinical promotion.
